Reddit Posts
Moving away from growth stocks & ETFs into CDs and T Bills
Moving away from growth stocks & ETFs into CDs and T Bills
#premarket #watchlist 11/08 $AUTL - Blackstone Life Sciences to invest up to $250 million in Autolus Therapeutics , $MYNZ - Mainz Biomed Commences Trading on Nasdaq Under Ticker Symbol ‘MYNZ’, $VLTA - Topgolf Partners With Volta... Any trading ideas? Welcome in comments! Also check my app!
I’m gonna get called a shill for this, really don’t care but I found something worth writing about.
Call me a shill for posting something other than AMC/GME (still holding those diamonds). I Yolo’d a few hundred into AUTL today. It might be the first legit cure for cancer. Just needs some volume. Not financial advice.
$AUTL 40k YOLO. 100% cancer remission confirmed Hodgkin lymphoma!
Autolus (ATL) 100% Remission on Cancer
Mentions
AUTL: Volume picking up and starting to move!
News on AUTL ? why is up ?
AUTL: About to make her move. Let's beat the shorts!
I'm not sure AUTL will make it that far down - it's meeting resistance at 1.37
AUTL: Nice volume...maybe wait for little dip.
AUTL is up, and could be a multibagger today based on their Leukemia Therapy Approval. # [https://www.stocktitan.net/news/AUTL/nice-recommends-aucatzyl-obecabtagene-autoleucel-as-a-treatment-dc7zf1u64n16.html](https://www.stocktitan.net/news/AUTL/nice-recommends-aucatzyl-obecabtagene-autoleucel-as-a-treatment-dc7zf1u64n16.html)
If AUTL get FDA approval I'm guessing they'll be acquired pretty quickly too, the results of their Obe-Cel trials have been outstanding
Currently holding: MBOT AMC Watching: NPWR TRUE TUYA WOOF AUTL CTOR CTXR LUCD
There is no question here for **PM Watchlist** : **$ASST** : hit overnight trading limit at 1.54$ in 3 minutes,called entry here at 0.85, congrats to those who’s in, if you can get in at this levels it’s easy 20% swing, don’t get greedy. **$GPUS** **$$IMG** , **$YDKG** --- Weekly plays : **$BITF** **$OPEN** : is still retail favorite and will climb **SLS** : RnD day Oct-29 **$AUTL** : Oct-28 treatment poster meeting . **$RR** : https://preview.redd.it/icsy2ug4ykxf1.jpeg?width=2640&format=pjpg&auto=webp&s=256ff2e41ecf3330ffc512546ad50b7c5d54c693
Since many of you asked to keep the tickers more than penny stocks, I threw them in. Also, overall XBI and biotech are in recovery mode. I’m still holding what I have, maybe add some PDUFA for early 2026, and added some commercial biotechs, AUTL, ADCT, ESPR, etc. cheers!
$BYND in this on Friday dip, failing company, shorted, artificial hype. Do not get greedy here, toxic Sec fillings. Money to be made though. $OPEN : still open **$AUTL** : **Oct-24** : https://www.sec.gov/Archives/edgar/data/1390478/000201238325002700/xslSCHEDULE_13G_X01/primary_doc.xml ___ **$SLS** : **Oct 17** : Black rock 5.5% : https://www.sec.gov/Archives/edgar/data/1390478/000201238325002700/xslSCHEDULE_13G_X01/primary_doc.xml **Oct-17/21** : Positive results presentation: https://www.sec.gov/Archives/edgar/data/1390478/000201238325002700/xslSCHEDULE_13G_X01/primary_doc.xml ___ Premarket: $LNKS : Continuation : AH PR: https://www.sec.gov/Archives/edgar/data/1972074/000121390025099733/ea026160201ex99-1_linkers.htm $SLRX $YYAI
In NUAI, DFLI, BITF & AUTL this week LFG 💪
Poor OP specially asked not to be shilled and comments with said shilling did not disappoint 😂. Posted this earlier hope it helps: Mid/Long term update: **$GNS** : little update for those who’s following : **Oct -14** : deadline set for filing case no later Nov-15 : https://www.sec.gov/Archives/edgar/data/1847806/000149315225017924/form6-k.htm ___ **$AUTL** : Catalyst **(Oct-24)** anticipation play not staying for PR: https://finviz.com/news/167010/autolus-therapeutics-to-present-clinical-data-update-at-the-american-college-of-rheumatology-acr-convergence-2025 ___ **$MIST** : Big one (**Dec-13**), desert (Nov7-10) : https://www.reddit.com/r/pennystocks/comments/1o2hmvw/mist_upcoming_catalysts/?share_id=sxkrm7CWNUgE7qceSCS0W&utm_content=1&utm_medium=ios_app&utm_name=ioscss&utm_source=share&utm_term=1
Look solid. I’m holding both **MIST** n **AUTL**
Mid/Long term update: **GNS** : little update for those who’s following : **Oct -14** : deadline set for filing case no later Nov-15 : https://www.sec.gov/Archives/edgar/data/1847806/000149315225017924/form6-k.htm ___ **$AUTL** : Catalyst **Oct-24** anticipation play not staying for PR: https://finviz.com/news/167010/autolus-therapeutics-to-present-clinical-data-update-at-the-american-college-of-rheumatology-acr-convergence-2025 ___ **$MIST** : Big one (Dec-13), desert (Nov7-10) : https://www.reddit.com/r/pennystocks/comments/1o2hmvw/mist_upcoming_catalysts/?share_id=sxkrm7CWNUgE7qceSCS0W&utm_content=1&utm_medium=ios_app&utm_name=ioscss&utm_source=share&utm_term=1
Checking in with you 1-year after your post OP. How's it going? Are you still bullish on AUTL? How about CABA? Curious where you stand today.
who knows, maybe we get lucky. For now I will hold with the shares that I have already. AUTL and GPUS are going to be my next swing trades, unless I see something better, any ideas?
AUTL could be a good play for next week for those who are looking to get in early. Do your own DD
Into AUTL for 6,492 shares @ 1.54. Let’s hope for a quick 20% return!
Into AUTL for 3,225 shares at $1.55. If it dips down to $1.50, I’ll probably throw another $5k at it for shits and giggles.
**$CRML** , **$BITF** , **$RR** , **ACHR** , **$GORV** into week. **$AUTL** : catalyst (Oct-24), looking for dips into 1.55 range for anticipation play, should be simple (15-30%), do not hold into PR date : [https://finviz.com/news/167010/autolus-therapeutics-to-present-clinical-data-update-at-the-american-college-of-rheumatology-acr-convergence-2025](https://finviz.com/news/167010/autolus-therapeutics-to-present-clinical-data-update-at-the-american-college-of-rheumatology-acr-convergence-2025) --- **$FEMY** , **$RVPH** , **$DFLI** \- easy 10%+ PM --- **$BITF** IMHO big long hold https://preview.redd.it/qy7nsylb5ftf1.jpeg?width=1284&format=pjpg&auto=webp&s=ae594393ecc895ac9ab9b9f911bf2f545409d7c1
**$CRML** , **$BITF** , **$RR** , **ACHR** into week. **$AUTL** : catalyst (Oct-24), looking for dips into 1.55 range for anticipation play, should be simple (15-30%), do not hold into PR date : [https://finviz.com/news/167010/autolus-therapeutics-to-present-clinical-data-update-at-the-american-college-of-rheumatology-acr-convergence-2025](https://finviz.com/news/167010/autolus-therapeutics-to-present-clinical-data-update-at-the-american-college-of-rheumatology-acr-convergence-2025) --- **$FEMY** , **$RVPH** , **$DFLI** \- easy 10%+ PM --- **$BITF** IMHO big long hold https://preview.redd.it/thlaj7tzoetf1.jpeg?width=1284&format=pjpg&auto=webp&s=acfd4a0b62733c815f1aff35528f2d7baeea746a
Just in case anyone is following me- nothing interesting here for me. I still have: CHRS, ANAB, NUVB, AUTL,HRTX, SPRY, PHAT. Will buy back BEAM, it was a mistake to sell it.
AUTL - dark pool volume shelf https://preview.redd.it/m2c37twgvvqf1.jpeg?width=1214&format=pjpg&auto=webp&s=ea9207584fc06833d3d13c9cabc1410c276e61a9
AUTL - dark pool orders in september https://preview.redd.it/yjign79evvqf1.jpeg?width=967&format=pjpg&auto=webp&s=945dcfeef1055e22cb5d7c808dc1bb1ada08b3af
Sold half my position in $SNDX and bought $AUTL. $SNDX still has a lot of upside and possible buy out that is why i left half in. $AUTL At a stock price of $1.57, a target of $9.62 suggests a 512.88% upside. Early stage commercial bio that is oversold. The only fda approved car-t therapy in development autoimmune indication.
$AUTL, early commercial stage bio that is oversold right now. Most likely a buy out candidate based on the CEO’s track record. His past three companies he was a part of got bought out!
AUTL. Get in before it takes off again
AUTL has been steadily gaining for months
I've picked 3 penny stocks to sit on for a couple weeks, all have promises of big gains: SANA, SKYX, and AUTL
AUTL - speaking at Goldman Sachs conference tomorrow
$IBRX $AUTL $BURU $FAAS diamond holders will be rewarded
Another ~+5% day for AUTL. Doubled in a month yet still completely flying under the radar. Going to be a big 6-12 mos.
AUTL… how many more 5+% days in a row until someone takes notice?
Might be able to unload my AUTL bags pretty soon at this rate
AUTL looking to run again today, gonna hit $2 early
AUTL been on a steady run for a month now. Just upped my position, think we'll see $2 before July
Seriously check out AUTL. Cancer treatment drug approved in Nov. 2024 and they are just now turning profit by treating patients. Holding for a year at $1.30 average and holding til $10
AUTL (Autolus) is better bet, but at this price IOVA could be low risk too.
https://www.stocktitan.net/news/AUTL/autolus-therapeutics-announces-license-of-aucatzyl-obecabtagene-5eyig71pfngp.html
AUTL on watch, randomly down 30 % on the week and just announced pretty decent news imo.
$MARA $AUTL 
Who wouldve thought AUTL would be the big winner today
AUTL with the surprise come from behind victory
https://preview.redd.it/tiqf4ddqs4ie1.jpeg?width=1200&format=pjpg&auto=webp&s=20ec979919d7d6436abee88b30cc99154502ab23 # Is AUTL currently the lowest float FDA approved large cap in the stock market? 99% stock held by institutions $657m cash, markt cap of $540m. Are things about to turn, some interesting names on that shareholder list with big positions.
i meant AUTL but i am also holding asts 😭😭😭 thank you though i do think ASTS is a good long term play.
Your post with title "AUTL opinions??" has been removed from r/pennystocks because it is too short. Posts must have at least 50 characters to ensure meaningful discussions. *I am a bot, and this action was performed automatically. Please [contact the moderators of this subreddit](/message/compose/?to=/r/pennystocks) if you have any questions or concerns.*
You would be deeply wrong to be so optimistic. You should also see how the street is receiving cell therapies at the moment — see AUTL, ADAP, CABA, et al. Even after approval, they’re getting wrecked because CAR-T has been proven in a majority of cases (as in, over 75% of patients in some cases) to produce secondary lymphomas (yes, a cancer treatment with a 75% likelihood of giving you _another_ form of cancer), ICANS, cytokine storm, neurotoxicity, and all other kinds of nasty AEs. They are finding the T Cells themselves in these secondary lymphomas, meaning the cells themselves are directly causing these adverse events. The FDA is likely going to put warnings to this effect on _all_ CAR T therapies, which is making the likelihood of them becoming first line treatments (i.e the treatment you would use when first diagnosed) very low. If a treatment can only be used for second or third line treatment, it immediately only has access to ~20% of the market, virtually signing its death warrant as a blockbuster drug, and severely limiting upside. Not to mention, it’s in Ph1, which only really tests safety and tolerance, rather than efficacy, on a much smaller patient population, no less. You will be waiting for _years_ to see _any_ traction, and even then, by the time that traction arrives, CAR T therapies might well be out of vogue. It’s an incredibly risky (read: unlikely to work out) play and you’d be better investing in something like AQST which has Anaphylm, a replacement for the epi-pen that uses a sublingual film instead of an injector. They recently hired the woman responsible for turning the epi-pen into one of the most profitable drugs of all time, so they’re internally very bullish on the prospects of the drug, and the TAM is huge, approval this year, sales in 2026, they already have an approved drug in Libervant, etc. As someone with experience in the industry, it’s about 10x the play that CERO is, please, listen to reason and re-evaluate. If not into AQST, into almost anything else, please, I beg you.
I'm going to do the reverse of doing the ol' definitely-not-a-bot-or-bagholder sort of DD. Cause I'm diamond-handing these stocks like a goofy goober. Don't put your money in AUTL, and don't put your money in AEXAF thinking that their restructuring is somehow going to fix their dogshit financials. And don't think RIME's high volume is indicative of positive movement.
no more catalysts... $AUTL presentations at ASH in a week, fingers crossed
It's not the same CR rate bro. 60%+ vs 42% in the label of AUTL. dingus
SYM and OKLO will be the giants tomorrow, with downs in PLTR ACHR PL and MSTR. Could see another up day for DPZ and a big positive correction for AUTL. If you're holding SYM and OKLO, you'll be in the money for sure
Funny that I see this here. I have been going over this with my brother, who is specializing in hematology. Couple key takeaways from our discussion below. I am not a clinician, so I’m trying to communicate this on a high level. Market and patient profile - there are multiple lines of defense here and there are likely 50-70% of ALL patients that would make it to the phase where you need this type of therapy - they are indicated for Adult, however, this cancer fairly common in pediatric patients. Although, adults with cancer experience greater relapse rates and more aggressive forms of ALL - AUTL has identified the TAM at 8000 patients and SAM at 3000 patients across US and EU… so about a $1.5B SAM - in the Jeffries healthcare conference, CEO noted that in the US, about 60 centers treat 90% of the patients and they are active in 30 of them Advantages to competitors - the safety profile of this therapy is a strong positive. Competing products have 20-30% grade 3+ infection rates, which means these patients are in the ICU longer and taking up hospital resources. One day in the ICU costs a hospital ~5-7K. So with a <5% grade 3+ infection risk means greater margins for hospitals, meaning more capacity to take on more acute procedures to generate incremental revenue - although a positive, the safety profile also opens up the door to where infusion therapy can be done in an outpatient setting. This means lower reimbursement… likely 30-40% lower, however, this is the only drug with the safety profile. Profit margins for outpatients procedures are significantly higher than inpatient Opportunity: - company EV is about 550M - company currently burns $200M per year - they would need 15% market share at 90% GM to likely break even - given the attributes noted above, I think 15-30% market share is attainable, or about 225-450M in revenue. Assuming a 4-5x EV/REV multiple, you are looking at 900M-2.2B potential EV value. - furthermore, this could be a good acquisition target for a larger company that has greater strengths in hospital contracting - upside risk appears to be worth the downside risk here based on these numbers - only issue I need to dig into further is all the agreements between Blackstone and BioNTech and is there are any triggers there that could drive equity dilution. It doesn’t seem like it but something I need dive deeper into Happy investing
This is not a good buy. A small company like this is never going to scale into the distribution channels it needs to make a profit. Then compound that by the low margin high capex needed for each dose. Keep in mind that this isn't an off the shelf therapy, it needs to be manufactured individually for each patient. Even the biggies are having a hard time turning a profit on CAR-T and the field is rapidly moving toward in vivo CAR delivery. AUTL is going to get left behind holding its own bag unless it expands the pipeline
Hey psst…don’t look now…but one $AUTL just happens to be on $GOOGL 13-F: https://www.sec.gov/Archives/edgar/data/1652044/000165204424000082/xslForm13F_X02/information_table.xml
DELL & AUTL
How do you evaluate the risks associated with AUTL, particularly in terms of its competitive landscape and financial sustainability?
If you don't buy, tomorrow you will see WSB littered with AUTL gains of $50k+. If you do buy, you will see loss porn.
Not OP but I asked ChatGPT for a high risk high reward stock and this is what it gave me: Investing your remaining amount in a high-risk, high-reward asset requires careful consideration, especially within an inherited IRA. Penny stocks—typically defined as stocks trading below $5 per share—can offer substantial returns but come with significant risks, including high volatility and low liquidity. **Potential Penny Stock Investment:** One option to consider is **Autolus Therapeutics Plc (AUTL)**: * **Overview:** Autolus is a biopharmaceutical company specializing in T-cell therapies for cancer treatment. * **Recent Performance:** As of November 23, 2024, AUTL was trading at $4.55, with a 30-day return of 25.3%. [Investopedia](https://www.investopedia.com/best-penny-stocks-8684104?utm_source=chatgpt.com) * **Technical Indicators:** The stock has shown bullish technical patterns, indicating potential upward momentum. **Considerations:** * **Volatility:** Penny stocks like AUTL can experience significant price swings, leading to potential rapid gains or losses. * **Liquidity:** Lower trading volumes may make it challenging to buy or sell shares without affecting the stock price. * **Research:** Thorough due diligence is crucial. Review the company's financial health, product pipeline, and market position.
AUTL reminds me of my artism. Fuck it I'm in
Nice. Honestly the reason I started researching AUTL because how little chatter there is among retail investors currently, paired with how good their outlook appears at quick glance. How did you find this stock?
$AUTl is another CAR-T play that hasn't taken off yet. Their CAR-T targets CD19 like CABA. $AUTL is FDA approved, $CABA phase 1/2... [https://www.reddit.com/r/wallstreetbetsOGs/comments/1h4rjnj/autlsafest\_fda\_approved\_cart\_therapy\_recently/](https://www.reddit.com/r/wallstreetbetsOGs/comments/1h4rjnj/autlsafest_fda_approved_cart_therapy_recently/)
$AUTL already has FDA approval and has proven reduced side effects.
it's all about risk, yes it's 5x the market cap, but phase 3 takes a year to run and FDA review another year. CABA literally burning cash around 70% of their market cap each year. Also there's the risk that FDA do not approve drug due to safety events or response. AUTL has proven that their therapy works and is the safest FDA-approved CAR-T therapy.
These medical stocks make me nervous. It’s definitely tempting but I just threw what I could afford into CABA. All these stocks (CABA, ACHR, AUTL, IPSC) all seem twins, with ACHR leading the pack. I’m weary even putting anything in CABA.
Tomorrow Buy AUTL and CABA
Phase 1 company, long road to FDA approval. By contrast, $AUTL recently fda approved CAR-T [https://www.reddit.com/r/pennystocks/comments/1h2rjky/autl\_fda\_approved\_cart\_currently\_in\_reversal\_from/](https://www.reddit.com/r/pennystocks/comments/1h2rjky/autl_fda_approved_cart_currently_in_reversal_from/)
$AUTL another CAR-T play w/ recently approved FDA treatment sitting near 52 week lows
CABA CABA is phase 1/2 CAR-T therapy on autoimmune. AUTL just got FDA approved CAR-T for ALL. They also have phase 1 readout for lupus is in Q1 2025. AUTL’s product is better than their competitors because of way less side effects and doesn’t need special facility permit. Share price in reversal from 52-week low. PSTX another phase 1 CAR-T got bought out by Roche for 1.5 bil. honestly out of all the CAR-T AUTL being fda approved sitting on cash close to sp is no brainer with MC of 800 The average price target by the analysts is $20+.
To be fair, even after this huge pump in CABA, they're still at a 180m market cap. AUTL is $880m, which seems pretty fully valued at this point?
FDA deemed $AUTL the safest CAR-T therapy... They are presenting their NEJM published trial at ASH in Dec [https://www.reddit.com/r/WallStreetbetsELITE/comments/1h2r2x0/autl\_another\_cart\_play\_with\_fda\_approved\_treatment/](https://www.reddit.com/r/WallStreetbetsELITE/comments/1h2r2x0/autl_another_cart_play_with_fda_approved_treatment/)
Saw your comment on the Caba post, do you think AUTL will have any catalysts in the near future?
It is a tremendous achievement. AUTL is company with first FDA approved CAR-T therapy that do not require FDA REMS, due to low rates of adverse events. People pumping CABA, but that is phase 1 with data on 1-2 patients. AUTL presenting data on lupus in Q1 2025. [https://www.stocktitan.net/news/AUTL/autolus-therapeutics-announces-fda-approval-of-aucatzyl-obecabtagene-zniz42td8z89.html](https://www.stocktitan.net/news/AUTL/autolus-therapeutics-announces-fda-approval-of-aucatzyl-obecabtagene-zniz42td8z89.html)
$AUTL is another CAR-T play. I just posted DD [https://www.reddit.com/r/WallStreetbetsELITE/comments/1h2r2x0/autl\_another\_cart\_play\_with\_fda\_approved\_treatment/](https://www.reddit.com/r/WallStreetbetsELITE/comments/1h2r2x0/autl_another_cart_play_with_fda_approved_treatment/)
Alright, take a deep breath because this rant is way off the mark. Let’s actually break down the nonsense you just spewed about CABA and CAR-T therapies. First, the whole “CAR-T is cancerous and gives people secondary lymphomas” argument is just plain wrong. Yes, CAR-T comes with risks—cytokine storm, neurotoxicity, and other side effects—but calling it “cancerous” is just lazy fearmongering. Secondary malignancies happen, sure, but they’re rare and nowhere near the “majority” of cases. You’re throwing out buzzwords like ICANS without context, ignoring the fact that CAR-T has saved lives in patients who had zero other options. This isn’t speculation; it’s clinical data. Now, dragging ADAP and AUTL into this like they somehow predict CABA’s future is ridiculous. Biotech isn’t some one-size-fits-all game where every company in a space performs the same. ADAP and AUTL have different pipelines, different targets, and, frankly, different execution. CABA isn’t just a CAR-T oncology play—it’s breaking into autoimmune disease, a market that isn’t as crowded and has insane potential. Painting the whole CAR-T field as doomed because you didn’t like how a couple of other stocks performed is straight-up amateur hour. Then there’s your hype for AQST and APLS, which sounds more like someone desperate to pump their own positions than an actual argument. Sure, AQST’s dissolvable epi-strip is a neat innovation, but it’s not even in the same universe as CAR-T in terms of medical impact. And while APLS and SWTX are interesting plays, comparing them to a completely different kind of therapy is like comparing apples to oranges. Investing in biotech isn’t about picking your “favorite” product like it’s some popularity contest. You diversify across different approaches and markets to balance risk and reward. Acting like one class of therapy inherently trumps another just shows you don’t understand the space. And the “CAR-T isn’t worth it” take? Please. CAR-T therapies like Kymriah and Yescarta are already blockbusters that transformed cancer care. Yes, the field has challenges—manufacturing, costs, side effects—but it’s evolving fast. CABA isn’t even sticking to the same old CAR-T playbook. They’re pivoting to autoimmune diseases, which could completely change the game. Writing them off because you’re clinging to outdated critiques of first-gen CAR-T is ignorant at best. Look, biotech is risky. Everyone knows that. But trashing CABA with half-baked arguments and acting like AQST or APLS is some magical low-risk goldmine doesn’t make you sound smarter. It just shows you’re more interested in ranting than actually understanding the sector. TL;DR: If you’re gonna go off on a company, at least back it up with facts instead of hyperbole and bad comparisons. Dismissing CABA without acknowledging its innovative approach is a rookie move.
Jesus fucking christ boys, what is it with you fucks and clinically regarded plays. CAR-T therapies are fucking cancerous, literally, in that the majority of patients that take them get secondary lymphomas (as well as other nasty after effects like ICANS, cytokine storm and neurotoxicities in three quarters of patients). Look at how ADAP and AUTL have been trading lately. Look at how AUTL traded after its PDUFA approval earlier this month. For fuck sake, at least pick a decent ticker that has a remote prospect of working out. You have AQST that literally makes epi-pens as a fucking dissolvable strip that goes under the tongue instead of a fucking needle, with potentially billions in TAM, and you want to invest in third line cancer treatments that are _likely give you another form of cancer_ when taken. Or APLS with a literal wagon of GA and C3G patients to sell to. Or SWTX with Ogsiveo for desmoid tumors and a PDUFA at the end of February, two fucking blockbuster drugs ($1bn/year in sales) and a market cap of less than $3bn. Fucking get it together.
For more context, see how AUTL, ADAP, etc. have been performing lately. See what happened with AUTL _after_ their PDUFA approval earlier this month.
I have some AUTL. It’s due for a run, because I’m down 50%
CABA makes CAR-T therapy and is in phase 1 for autoimmune. Another CAR-T play is $AUTL: phase 3 CAR-T just approved sitting close to cash. Phase 3 showed AUTL's CAR-T was better than competitors due to less adverse events. Revenue realization in Q1 2025 and $AUTL will also be presenting data on lupus in Q1 2025. I did a post earlier [https://www.reddit.com/r/Shortsqueeze/comments/1gvf0a7/autl\_cancer\_biotech\_gem\_near\_all\_time\_lows/](https://www.reddit.com/r/Shortsqueeze/comments/1gvf0a7/autl_cancer_biotech_gem_near_all_time_lows/)
Once the fun is over, take a look at $AUTL, it has FDA approved CAR-T better than others in a number of ways. I think this field is hot considering PSTX a phase 1/2 got bought out last week
CABA is phase 1/2 CAR-T therapy on autoimmune. AUTL just got FDA approved CAR-T for ALL. They also have phase 1 readout for lupus is in Q1 2025. AUTL's product is better than their competitors because of way less side effects and doesn't need special facility permit. Share price in reversal from 52-week low. PSTX another phase 1 CAR-T got bought out by Roche for 1.5 bil. honestly out of all the CAR-T AUTL being fda approved sitting on cash close to sp is no brainer with MC of 800 mil
CABA is interesting CAR-T for autoimmune. AUTL with recently approved CAR-T for ALL with potential to displace tcarteous is presenting phase 1 data on SLE in Q1 2025.
Their candidate for covid is not sexy at all. COVID much more mild now. ABCL also had an EUA for antibody for COVID19 that's worthless now. TNYA curing ppl of heart conditions with 1 dose sexy af. Check out AUTL CAT-T disruptor just approved trading less than when the news dropped. They also doing a trial for autoimmune. I did a write up earlier [https://www.reddit.com/r/Shortsqueeze/comments/1gvf0a7/autl\_cancer\_biotech\_gem\_near\_all\_time\_lows/](https://www.reddit.com/r/Shortsqueeze/comments/1gvf0a7/autl_cancer_biotech_gem_near_all_time_lows/)
What is the target price of AUTL?
The post says 25.3% return for AUTL in the past 30 days. I’m not seeing that trend in the stock price. What’s missing? Can someone please explain? https://preview.redd.it/rbfslku2bx2e1.jpeg?width=1284&format=pjpg&auto=webp&s=c2bc270ae6095960294b65bb56fd959e6f49be2f
$AUTL fda approved on 11/8/24 stock at 52 week lows, 75% tute ownership, $2.5 cash per share and SP of $3.
It's cheaper to go in $AUTL as they will be getting commercial license in November
$AUTL - Follow-up Data for Phase 2 study released and looking good. Holding for PDUFA later this year $ADAP - Collaboration agreement last week, stock waiting for PDUFA - good cash position from last ER $ANVS - Data readout for June for drug for Parkinsons Disease. Stock loves to run. Lots of insiders holding. $ALT - It’s ALT, down, will probably bounce back up.